Sancuso is owned by Kyowa Kirin.
Sancuso contains Granisetron.
Sancuso has a total of 1 drug patent out of which 0 drug patents have expired.
Sancuso was authorised for market use on 12 September, 2008.
Sancuso is available in film, extended release;transdermal dosage forms.
Sancuso can be used as use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting.
The generics of Sancuso are possible to be released after 22 January, 2025.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7608282||KYOWA KIRIN||Transdermal granisetron|| |
(1 year, 11 months from now)
Market Authorisation Date: 12 September, 2008
Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic